好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Longitudinal brain and skeletal muscle FDG-PET changes in people with stiff person syndrome spectrum disorders
Autoimmune Neurology
P4 - Poster Session 4 (8:00 AM-9:00 AM)
6-021
To describe changes in fluorodeoxyglucose positron emission tomography (FDG-PET) findings in the brain and muscles of individuals with stiff person syndrome spectrum disorders (SPSD) longitudinally.
SPSD includes multiple clinical phenotypes that rarely can be paraneoplastic in origin. An FDG-PET scan is frequently obtained as part of the malignancy work-up, and abnormal metabolic activity unrelated to malignancy has been shown to occur in both the brain and skeletal muscles of patients with SPSD. However, it is unclear if such findings persist or change over time.
A retrospective study was performed of patients with SPSD who were seen at Johns Hopkins SPS Center from 2009 to March 2022, with at least two FDG-PET studies in the medical record with source images of sufficient quality for comparison. Quantitative data was extracted from dedicated brain FDG-PET scans using NeuroQ™, which calculates Z-scores of 47 brain regions compared to healthy controls. Body FDG-PET scans will be reviewed qualitatively by a blinded nuclear medicine radiologist to detect the presence and pattern of hypermetabolism in skeletal muscle. Patients’ clinical characteristics, including type of treatment, will be correlated with PET data.

Out of 98 SPSD patients who underwent an FDG-PET scan, 10 were identified that met inclusion criteria. Median age at time of SPSD onset was 51±15.8 years, 60% were males, and 60% were black.  Mean duration from symptom onset to first FDG-PET scan was 0.78±0.62 years. The majority of patients had SPS-plus phenotype. All patients were seropositive for an SPSD-associated antibody and received an immune therapy. Preliminary data demonstrate that all patients had at least 1 region of dysmetabolism on initial brain scan, and at least 3 regions on follow-up.

We will present longitudinal metabolic changes in brain and body FDG-PET scans of patients with SPSD, and determine if any changes observed are associated with clinical characteristics.
Authors/Disclosures
Samantha Roman, MD (Johns Hopkins Hospital)
PRESENTER 		Dr. Roman has nothing to disclose.
Yujie Wang, MD (UW Northwest) Dr. Wang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Wang has received research support from Genentech. The institution of Dr. Wang has received research support from uniQure. The institution of Dr. Wang has received research support from NIH/NINDS.
No disclosure on file
Scott D. Newsome, DO, FAAN (Johns Hopkins Hospital) Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Newsome has received research support from Biogen. The institution of Dr. Newsome has received research support from Genentech/Roche. The institution of Dr. Newsome has received research support from Department of Defense. The institution of Dr. Newsome has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Newsome has received research support from National MS Society. The institution of Dr. Newsome has received research support from Lundbeck. The institution of Dr. Newsome has received research support from Sanofi. The institution of Dr. Newsome has received research support from Kyverna Therapeutics. Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving as a Lead PI for Clinical Trial with Roche.